<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091039</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000383146</org_study_id>
    <secondary_id>NCI-04-C-0252</secondary_id>
    <secondary_id>NCI-6439</secondary_id>
    <nct_id>NCT00091039</nct_id>
    <nct_alias>NCT00088725</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery</brief_title>
  <official_title>A Pilot Trial of a CEA/TRICOM-Based Vaccine in Combination With Combined Chemotherapy/Radiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a gene-modified virus may make the body build an immune&#xD;
      response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin,&#xD;
      work in different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
      Radiation therapy uses high energy x-rays to damage tumor cells. Combining vaccine therapy&#xD;
      with chemotherapy and radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving vaccine therapy together with&#xD;
      paclitaxel, carboplatin, and radiation therapy works in treating patients with stage III&#xD;
      non-small cell lung cancer that cannot be removed with surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and feasibility of standard paclitaxel, carboplatin, and&#xD;
           radiotherapy in combination with vaccinia-CEA-TRICOM vaccine, fowlpox-CEA-TRICOM&#xD;
           vaccine, and recombinant fowlpox GM-CSF vaccine in patients with unresectable stage III&#xD;
           non-small cell lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine clinical response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine time to disease progression and overall median survival of patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine immunologic response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Vaccine: Patients receive vaccinia-CEA-TRICOM vaccine subcutaneously (SC) on day 0 and&#xD;
           fowlpox-CEA-TRICOM (rF-CEA-TRICOM) vaccine SC on days 14, 29, 43, 57, 70, 91, and 112.&#xD;
           Patients also receive recombinant fowlpox GM-CSF (rF-GM-CSF) vaccine SC with each&#xD;
           vaccination. Patients with stable or responding disease after day 112 continue to&#xD;
           receive rF-CEA-TRICOM and rF-GM-CSF SC every 3 weeks in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Radiotherapy: Patients undergo radiotherapy on days 21-25, 28-32, 35-39, 42-46, 49-53,&#xD;
           56-60, and 63-67.&#xD;
&#xD;
        -  Chemotherapy: Concurrently with radiotherapy, patients receive paclitaxel IV over 1 hour&#xD;
           and carboplatin IV over 30 minutes on days 21, 28, 35, 42, 49, 56, and 63. Patients also&#xD;
           receive paclitaxel and carboplatin on days 91 and 112 (after completion of&#xD;
           radiotherapy).&#xD;
&#xD;
      Patients are followed annually for up to 15 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 4-6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant fowlpox GM-CSF vaccine adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant fowlpox-CEA(6D)/TRICOM vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant vaccinia-CEA(6D)-TRICOM vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Stage III (locally advanced) disease&#xD;
&#xD;
          -  Unresectable disease&#xD;
&#xD;
          -  Carcinoembryonic antigen (CEA)-positive (staining ≥ 20% of cells) tumor by&#xD;
             immunohistochemistry&#xD;
&#xD;
          -  HLA-A2-positive&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Absolute lymphocyte count ≥ 600/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  AST ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  Hepatitis B and C negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable or newly diagnosed angina pectoris&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No altered immune function&#xD;
&#xD;
          -  No active or history of eczema&#xD;
&#xD;
          -  No atopic dermatitis&#xD;
&#xD;
          -  No autoimmune disease, including any of the following:&#xD;
&#xD;
               -  Autoimmune neutropenia, thrombocytopenia, or hemolytic anemia&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Sjögren's syndrome&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Myasthenia gravis&#xD;
&#xD;
               -  Goodpasture's syndrome&#xD;
&#xD;
               -  Addison's disease&#xD;
&#xD;
               -  Hashimoto's thyroiditis&#xD;
&#xD;
               -  Active Graves' disease&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
          -  No known history of allergy or serious reaction to prior vaccination with vaccina&#xD;
&#xD;
          -  No known allergy to eggs&#xD;
&#xD;
          -  No active or history of extensive psoriasis, severe acneiform rash, impetigo,&#xD;
             varicella zoster, burns, or other traumatic or pruritic skin condition&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 months after study&#xD;
             participation&#xD;
&#xD;
          -  No history of seizures or encephalitis&#xD;
&#xD;
          -  Able to avoid close household contact with the following individuals for at least 3&#xD;
             weeks after vaccinia vaccination:&#xD;
&#xD;
               -  Children under 3 years of age&#xD;
&#xD;
               -  Pregnant or nursing women&#xD;
&#xD;
               -  Individuals with a history of or active eczema or other eczematoid skin disorders&#xD;
&#xD;
               -  Individuals with other acute, chronic, or exfoliative skin conditions (e.g.,&#xD;
                  atopic dermatitis, impetigo, burns, varicella zoster, severe acne, or other open&#xD;
                  rashes or wounds)&#xD;
&#xD;
               -  Immunodeficient or immunosuppressed individuals, including HIV-positive persons,&#xD;
                  by disease or therapy&#xD;
&#xD;
          -  No other active malignancy within the past 2 years&#xD;
&#xD;
          -  No other concurrent serious illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 years since prior immunotherapy with related vaccinia and fowlpox vaccines&#xD;
&#xD;
          -  At least 3 years since prior antigen-specific peptides&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior paclitaxel or carboplatin for lung cancer&#xD;
&#xD;
          -  At least 3 years since prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids, except for any of the following:&#xD;
&#xD;
               -  Topical steroids&#xD;
&#xD;
               -  Inhaled steroids for mild or moderate asthma&#xD;
&#xD;
               -  Dexamethasone as premedication for paclitaxel OR for short-term doses (48-72&#xD;
                  hours in duration) to control refractory nausea that is not responding to other&#xD;
                  antiemetics&#xD;
&#xD;
               -  Systemic corticosteroids for ≥ grade 3 radiation pneumonitis&#xD;
&#xD;
          -  No steroid eye-drops for at least 3 weeks after vaccinia vaccination&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  No concurrent systemic glucocorticoids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the lung fields&#xD;
&#xD;
          -  No prior thoracic radiotherapy for lung cancer&#xD;
&#xD;
          -  No other concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Surgical scars must be healed&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  No concurrent major surgical procedure&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No other concurrent anticancer agent or therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip M. Arlen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2004</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

